South Africa’s main equities gauge advanced 0.1% by 9:45 a.m. in Johannesburg as Life Healthcare Group Holdings soared after the US Food and Drugs Administration approved Biogen’s Alzheimer’s drug. The FDA approval makes Biogen the first new Alzheimer’s drug in almost 20 years. Life Healthcare rose as much as 18% to the highest level since April 2019. Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process. You will be redirected to a checkout page.
To view all features and options, click here. A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership. Investors in South Africa are awaiting the release of South Africa’s first-quarter GDP, which will probably show Africa’s most industrialised economy expanded by an annualised 3.2% in the three months through March from the previous quarter, according to the median estimate of economists in a Bloomberg survey. Peers in a number of Asian markets edged back Tuesday as investors await more clues on whether the recovery from the pandemic will stoke price pressures and imperil loose monetary policy.